The story of Viagra presents a complex picture for shareholders. While the initial launch generated significant profits, the end of its patent opened the avenue to generic versions, dramatically eroding market share. This creates a unique risk for firms depending on related blockbuster products, suggesting that a blind investment in the sector may

The history of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, producing billions in income, its patent expiration created a deluge of lower-priced alternatives , significantly diminishing its position . While specific businesses may try to capitalize on male sexual dysfunction, the